Merrimack Pharmaceuticals (NASDAQ: MACK)
Some price data may be temporarily unavailable.
Merrimack Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Merrimack Pharmaceuticals Company Info
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
News & Analysis
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
Why iRobot, Golar LNG, and Merrimack Pharmaceuticals Slumped Today
These stocks led the market lower. Find out why.
Why Merrimack Pharmaceuticals Stock Is Tanking Today
The biotech's managerial shake-up is wreaking havoc on its share price.
Is Merrimack Pharmaceuticals Worth Stashing in Portfolios?
This biotech hopes to recapture its luster following a major restructuring.
3 Stocks Begging for a Buyout
Here's why it could make sense for Twitter, GoPro, and Merrimack Pharmaceuticals to get acquired.
Why Merrimack Pharmaceuticals Got Crushed 23.8% in January
Investors fled the stock after the company announced a major restructuring of its business.
Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today
Merrimack hits the reset button.
Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016
It was an eventful year for the commercial-stage biotech. Let's take a closer look at the key events that caused the company's stock to get cut in half.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.